Jean Bourhis1, Wendy Jeanneret Sozzi2, Patrik Gonçalves Jorge3, Olivier Gaide4, Claude Bailat5, Fréderic Duclos2, David Patin2, Mahmut Ozsahin2, François Bochud5, Jean-François Germond5, Raphaël Moeckli5, Marie-Catherine Vozenin6. 1. Department of Radiation Oncology, Lausanne University Hospital and University of Lausanne, Switzerland; Radiation Oncology Laboratory, Department of Radiation Oncology. Lausanne University Hospital and University of Lausanne, Switzerland. Electronic address: jean.bourhis@chuv.ch. 2. Department of Radiation Oncology, Lausanne University Hospital and University of Lausanne, Switzerland. 3. Department of Radiation Oncology, Lausanne University Hospital and University of Lausanne, Switzerland; Radiation Oncology Laboratory, Department of Radiation Oncology. Lausanne University Hospital and University of Lausanne, Switzerland; Institute of Radiation Physics, Lausanne University Hospital and University of Lausanne, Switzerland. 4. Department of Dermatology, Lausanne University Hospital and University of Lausanne, Switzerland. 5. Institute of Radiation Physics, Lausanne University Hospital and University of Lausanne, Switzerland. 6. Department of Radiation Oncology, Lausanne University Hospital and University of Lausanne, Switzerland; Radiation Oncology Laboratory, Department of Radiation Oncology. Lausanne University Hospital and University of Lausanne, Switzerland.
Abstract
BACKGROUND: When compared to conventional radiotherapy (RT) in pre-clinical studies, FLASH-RT was shown to reproducibly spare normal tissues, while preserving the anti-tumor activity. This marked increase of the differential effect between normal tissues and tumors prompted its clinical translation. In this context, we present here the treatment of a first patient with FLASH-RT. MATERIAL & METHODS: A 75-year-old patient presented with a multiresistant CD30+ T-cell cutaneous lymphoma disseminated throughout the whole skin surface. Localized skin RT has been previously used over 110 times for various ulcerative and/or painful cutaneous lesions progressing despite systemic treatments. However, the tolerance of these RT was generally poor, and it was hypothesized that FLASH-RT could offer an equivalent tumor control probability, while being less toxic for the skin. This treatment was given to a 3.5-cm diameter skin tumor with a 5.6-MeV linac specifically designed for FLASH-RT. The prescribed dose to the PTV was 15 Gy, in 90 ms. Redundant dosimetric measurements were performed with GafChromic films and alanine, to check the consistency between the prescribed and the delivered doses. RESULTS: At 3 weeks, i.e. at the peak of the reactions, a grade 1 epithelitis (CTCAE v 5.0) along with a transient grade 1 oedema (CTCAE v5.0) in soft tissues surrounding the tumor were observed. Clinical examination was consistent with the optical coherence tomography showing no decrease of the thickness of the epidermis and no disruption at the basal membrane with limited increase of the vascularization. In parallel, the tumor response was rapid, complete, and durable with a short follow-up of 5 months. These observations, both on normal skin and on the tumor, were promising and prompt to further clinical evaluation of FLASH-RT. CONCLUSION: This first FLASH-RT treatment was feasible and safe with a favorable outcome both on normal skin and the tumor.
BACKGROUND: When compared to conventional radiotherapy (RT) in pre-clinical studies, FLASH-RT was shown to reproducibly spare normal tissues, while preserving the anti-tumor activity. This marked increase of the differential effect between normal tissues and tumors prompted its clinical translation. In this context, we present here the treatment of a first patient with FLASH-RT. MATERIAL & METHODS: A 75-year-old patient presented with a multiresistant CD30+ T-cell cutaneous lymphoma disseminated throughout the whole skin surface. Localized skin RT has been previously used over 110 times for various ulcerative and/or painful cutaneous lesions progressing despite systemic treatments. However, the tolerance of these RT was generally poor, and it was hypothesized that FLASH-RT could offer an equivalent tumor control probability, while being less toxic for the skin. This treatment was given to a 3.5-cm diameter skin tumor with a 5.6-MeV linac specifically designed for FLASH-RT. The prescribed dose to the PTV was 15 Gy, in 90 ms. Redundant dosimetric measurements were performed with GafChromic films and alanine, to check the consistency between the prescribed and the delivered doses. RESULTS: At 3 weeks, i.e. at the peak of the reactions, a grade 1 epithelitis (CTCAE v 5.0) along with a transient grade 1 oedema (CTCAE v5.0) in soft tissues surrounding the tumor were observed. Clinical examination was consistent with the optical coherence tomography showing no decrease of the thickness of the epidermis and no disruption at the basal membrane with limited increase of the vascularization. In parallel, the tumor response was rapid, complete, and durable with a short follow-up of 5 months. These observations, both on normal skin and on the tumor, were promising and prompt to further clinical evaluation of FLASH-RT. CONCLUSION: This first FLASH-RT treatment was feasible and safe with a favorable outcome both on normal skin and the tumor.
Authors: Neil G Burnet; Ranald I Mackay; Ed Smith; Amy L Chadwick; Gillian A Whitfield; David J Thomson; Matthew Lowe; Norman F Kirkby; Adrian M Crellin; Karen J Kirkby Journal: Br J Radiol Date: 2020-01-14 Impact factor: 3.039
Authors: Andrew J Johnsrud; Samir V Jenkins; A Jamshidi-Parsian; Charles M Quick; Edvaldo P Galhardo; Ruud P M Dings; Kieng B Vang; Ganesh Narayanasamy; Issam Makhoul; Robert J Griffin Journal: Radiat Res Date: 2020-12-01 Impact factor: 2.841
Authors: Noora H Ba Sunbul; Wei Zhang; Ibrahim Oraiqat; Dale W Litzenberg; Kwok L Lam; Kyle Cuneo; Jean M Moran; Paul L Carson; Xueding Wang; Shaun D Clarke; Martha M Matuszak; Sara A Pozzi; Issam El Naqa Journal: Med Phys Date: 2021-09-08 Impact factor: 4.071
Authors: Dylan Yamabe Breitkreutz; Muhammad Shumail; Karl K Bush; Sami G Tantawi; Peter G Maxime; Billy W Loo Journal: Radiat Res Date: 2020-12-01 Impact factor: 2.841
Authors: Luis A Soto; Kerriann M Casey; Jinghui Wang; Alexandra Blaney; Rakesh Manjappa; Dylan Breitkreutz; Lawrie Skinner; Suparna Dutt; Ryan B Ko; Karl Bush; Amy S Yu; Stavros Melemenidis; Samuel Strober; Edgar Englemann; Peter G Maxim; Edward E Graves; Billy W Loo Journal: Radiat Res Date: 2020-12-01 Impact factor: 2.841
Authors: J Ramos-Méndez; N Domínguez-Kondo; J Schuemann; A McNamara; E Moreno-Barbosa; Bruce Faddegon Journal: Radiat Res Date: 2020-10-02 Impact factor: 2.841